Research & Clinical Trials - Non-Hodgkins Lymphoma (NHL)
Several drugs for Non Hodgkins lymphoma being researched are in the clinical trial phase.
Malignant tumor cell surface have different antigens when compared to normal cells. Using this fact to advantage, Monoclonal Antibodies (MAB) were developed in the nineties for the treatment of NHL. There are newer MABs that are being invented all the time and tested by conducting clinical trials.
A Phase II, single arm study to test T -cell immunotherapy in individuals with indolent non-Hodgkin#$#s lymphoma (NHL) is underway. The candidates for the study are those with relapsed or refractory disease, after receiving 1- 4 prior regimens. Patients are administered Xcellerated T Cells TM, a T cell product, to enhance immune responses against tumors. The primary aim of the study is to assess the efficacy of these Xcellerated T Cells in patients suffering from indolent NHL. The study also aims at evaluating the safety of the therapy in the subject population.
Several clinical trials are assessing the effectiveness of Radioimmunotherapy as a first treatment option and also as a treatment prior to stem cell therapy.
